Press Release

Printer Friendly Version View printer-friendly version
<< Back
POZEN Inc. Announces Favorable Preliminary Results for MT 100 Six-Month p53 Mouse Carcinogenicity Study

CHAPEL HILL, N.C., Jan 29, 2002 /PRNewswire-FirstCall via COMTEX/ -- POZEN Inc. (Nasdaq: POZN) announced today that the preliminary results of the company's first carcinogenicity study for its lead product candidate, MT 100, indicate that MT 100 is not carcinogenic in the test species, transgenic p53 mice. Results from the ongoing two-year rat carcinogenicity study will be available in 2003.

John R. Plachetka, Pharm.D., chairman, president and chief executive officer of POZEN, said, "We are very pleased with these favorable preliminary data. As part of our ongoing dialogue with the FDA concerning this issue, we will submit the study report within the next few weeks."

MT 100 is being developed as an oral, first-line treatment for migraine pain and associated symptoms. The effectiveness of the product candidate has been demonstrated in numerous Phase II and Phase III clinical studies involving thousands of patients. Last year the company announced that MT 100 provided comparable efficacy with fewer side effects when tested against Imitrex(R), the worldwide market leader.

North Carolina-based POZEN Inc. is a pharmaceutical development company committed to building a portfolio of products with significant commercial potential in select therapeutic areas. POZEN's initial focus is on developing products for migraine therapy, a global market expected to exceed $2.6 billion this year. The company's common stock is traded on The Nasdaq Stock Market under the symbol "POZN."

Statements included in this press release that are not historical in nature are "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. You should be aware that our actual results could differ materially from those contained in the forward-looking statements, which are based on management's current expectations and are subject to a number of risks and uncertainties, including, but not limited to, our failure to successfully commercialize MT 100 and our other products; costs and delays in the development of MT 100 and our other products; our inability to enter into or maintain, and the risks resulting from our dependence upon, collaboration or contractual arrangements necessary for the development, manufacture, commercialization, marketing, sales and distribution of our products; competitive factors; our inability to protect our patents or proprietary rights and obtain necessary rights to third party patents and intellectual property to operate our business; our inability to operate our business without infringing the patents and proprietary rights of others; general economic conditions; the failure of our products to gain market acceptance; our inability to obtain any additional required financing; technological changes; government regulation; changes in industry practice; and one-time events, including those discussed herein and in our Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2001 under "Management's Discussion and Analysis of Financial Condition and Results of Operations." We do not intend to update any of these factors or to publicly announce the results of any revisions to these forward-looking statements.

POZEN is on the Internet at

Matt Czajkowski
Chief Financial Officer, of POZEN
General Inquiries
Kathy Brunson of FRB Weber Shandwick

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.